Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Esperion

- PMLiVE

Novo Nordisk and Ascendis enter $285m partnership for once-monthly GLP-1 drug

The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases

- PMLiVE

Merck’s Winrevair receives EC approval to treat pulmonary arterial hypertension in adults

About 30,000 people in the EU are living with the progressive blood vessel disorder

- PMLiVE

Novo Nordisk receives CHMP recommendation for Wegovy cardiovascular label update

The weight management drug was found to significantly reduce the risk of major adverse cardiovascular events

- PMLiVE

Novo Nordisk to acquire cardiovascular disease specialist Cardior in deal worth over €1bn

The deal includes a candidate being evaluated in a mid-stage trial to treat heart failure patients

- PMLiVE

New blood test to reduce heart attacks and death rates in A&E heart patients

The test could improve diagnosis for one in five patients with a heart muscle injury

- PMLiVE

Risk calculator to prevent heart attacks and strokes in type 2 diabetes patients

About one-third of adults living with diabetes die from a heart or circulatory disease

- PMLiVE

EDX Medical Group develops multi-disease ‘point-of-care’ rapid tests for cancer, infections and cardiovascular conditions

The development follows the Group’s acquisition of Hutano Diagnostics

- PMLiVE

Esperion’s heart drug shown to reduce risk of major adverse cardiovascular events

Cardiovascular diseases result in an estimated 17.9 million deaths each year

- PMLiVE

Esperion gets FDA thumbs up for cholesterol drug Nexletol

Big comeback after previous trial fail

- PMLiVE

Amarin files fish oil-based heart drug Vascepa in Europe

FDA verdict is also due for expanded use of the drug

- PMLiVE

Amarin wins FDA advisory nod for Vascepa cardiovascular expansion

Approval likely for fish-oil derived drug following speedy review

- PMLiVE

Esperion craters as deaths mar atherosclerosis drug study

But the company insists its atherosclerosis candidate didn’t cause the deaths

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links